The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes is a science podcast hosted by Unknown Host, with 128 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes, a science show with 128 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup | Amylyx Avexitide Wins Phase 3: 55% Fewer Hypoglycemic Events, Filing at Stake

  Aug 18, 202612 min

  Amylyx's avexitide cut serious hypoglycemic events 55% in Phase 3, sending shares up 54% to a three-year high - on a drug bought for $35 million out of bankruptcy. We break down BioMarin's $275 million Alesta acquisition and oral hypophosphatasia candidate ALE1, Leo Pharma's $435 million dersimelagon license from Tanabe in erythropoietic protoporphyria, EyePoint's 67% Duravyu crash in wet AMD against Eylea, and Moderna's mFlusiva mRNA flu vaccine approval. Visit us at thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup | EyePoint Crashes 67% After Duravyu Fails Phase 3 in Wet AMD

  Aug 17, 202612 min

  EyePoint stock crashed 67% after Duravyu missed its primary endpoint against aflibercept in the LUGANO Phase 3 for wet AMD - with nine vision-loss cases in the treatment arm versus zero. Also: argenx's Vyvgart Hytrulo hits in autoimmune myositis, AstraZeneca scraps its volrustomig bispecific in lung cancer while Enhertu and Tagrisso win, Sandoz signs a $322M biosimilar deal with Shanghai Henlius, Cytokinetics sues Bristol Myers Squibb over aficamten and Camzyos, and Slate Medicines merges with Fulcrum Therapeutics. Visit us at thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Week in Review | Lilly's Retatrutide Lawsuits: Enforcing a Drug Nobody Has Approved

  Aug 16, 202614 min

  Eli Lilly filed six lawsuits over black-market retatrutide and has referred more than 200 sellers to regulators — before it has even filed for approval. Plus Bristol Myers Squibb's accelerated approval of Zenbexus (iberdomide) with Darzalex in multiple myeloma on a 41% versus 21% MRD-negative complete response, Taiho and Cullinan's early Phase 3 unblinding for zipalertinib in EGFR exon 20 lung cancer, Silence Therapeutics' 88% versus 19% divesiran result in polycythemia vera, and Rhythm's UK expansion for IMCIVREE in acquired hypothalamic obesity. Visit us at thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup | Zenbexus Approval Tests a New Endpoint: What BMS Still Owes the FDA

  Aug 14, 202611 min

  BMS won FDA accelerated approval for Zenbexus on a 41% versus 21% MRD-negative complete response — with no survival data required. We break down what the first CELMoD approval means for Bristol Myers' Revlimid replacement strategy, why the CD38-pretreated label limit caps the launch, and the confirmatory readout still owed. Plus Capricor's 71% surge on a refined deramiocel filing in Duchenne muscular dystrophy, Taiho and Cullinan's early-stopped Phase 3 for zipalertinib in EGFR exon 20 lung cancer, and the Skye–Redx reverse merger creating Fibrx Therapeutics with $125 million for fibrostenotic Crohn's. Visit us at thepharmacloseout.com.

  ListenShow Notes
• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Daily Roundup | Definium LSD Pill Beats Placebo in Phase 3 Anxiety Trial

  Aug 13, 202610 min

  Definium's DT120 separated from placebo by 5.4 points in Phase 3 generalized anxiety — from a single dose of pharmaceutical-grade LSD. Also: Taiho and Cullinan halt a first-line EGFR exon 20 lung cancer trial early with zipalertinib, raising the bar for J&J's Rybrevant, AstraZeneca and Dizal's Zegfrovy, and ArriVent's firmonertinib. Plus Karyopharm faces default on a September loan payment as it files Xpovio in myelofibrosis, and Eli Lilly escalates its fight against the retatrutide black market. Visit us at thepharmacloseout.com.

  ListenShow Notes

Recent guests on The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.